First day of trading in warrants of series TO1 Eevia Health Plc ("Eevia" or the "Company") carried out a rights issue of shares and warrants (the "Rights Issue") in June/July 2024. The first day of trading in warrants of seri...
FLAGGING OF PURCHASE OF SHARES AND MAJOR CHANGE OF HOLDINGS BY PMDR IN EEVIA HEALTH PLC Betulum AS ("Betulum"), a close associate of Martin Bjørklund, the chairman of the board of Eevia Health Plc ("Eevia" or "The Company"), has purchased 1,000,000 shares in Eevia H...
FLAGGING OF PURCHASE OF SHARES AND MAJOR CHANGE OF HOLDINGS BY PMDR IN EEVIA HEALTH PLC Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc ("Eevia" or "The Company"), has purchased 525 800 shares in Eevia Health Plc.
Eevia Health receives multiple sales orders for c. KSEK 1 000 (KEUR 92) Eevia Health PLC ("Eevia" or "The Company") received several sales orders for extracts totaling KEUR 92 from various European, Australian, and American customers.[1]
Eevia Lands First Order for Side Stream Product c. KSEK 342 (KEUR 30) Eevia Health PLC ("Eevia" or "The Company") received the first sales order from a new pilot customer for two of its liquid sugar concentrates, which are side streams from the ber...
REG MAR
Eevia Health Plc Interim Report Q2 - 2024 The Board and CEO of Eevia Health Plc present the Interim Financial Report for quarter 2, 2024.
Last day of trading in paid subscription shares (Sw. BTA) in Eevia Eevia Health Plc's ("Eevia" or "the Company") rights issue has now been registered with the Finnish Trade Register and the shares have been delivered to Euroclear Sweden today an...
Eevia Health receives a 927 KSEK (80 KEUR) sales order for a Lingonberry extract Eevia Health Plc ("Eevia" or "The Company") has received an 80 KEUR sales order for Lingonberry extracts from a Finnish beauty brand.
CORRECTION: Eevia publishes the outcome of the rights issue In the previous press release, 281,200 shares and 70,300 warrants that had been subscribed for in Finland with subscription rights had not been accounted for in the summary prese...
REG
CORRECTION: Eevia publishes the outcome of the rights issue THE PRESS RELEASE WAS SENT OUT WITH THE MAR LABEL, WHICH IS INCORRECT. THEREFORE, WE RESEND WITHOUT THE MAR LABEL.THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS NOT INTENDED...
REG MAR
Eevia publishes the outcome of the rights issue THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS NOT INTENDED TO BE PUBLISHED, DISCLOSED, OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KO...
REG
Eevia has stopped the liquidity arrangement at Spotlight Stockmarket Eevia Health Abp ("Eevia Health" or the "Company") has ended the arrangement with Mangold Fondkommission act as a liquidity provider for the company's shares at the Spotlight Sto...
Eevia Health secures an 868 KSEK sales order from a new customer for a new superior polyphenol extract Eevia Health Plc ("Eevia" or "The Company") has won a 77 KEUR (868 KSEK) sales order from a new North American brand owner. The order is the first commercial customer for Feno-Ce...
REG
Communique from the Annual General Meeting in Eevia Health Plc 2024 The Annual General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on June 28, 2024, in Seinäjoki, Finland.
Eevia Health Plc receives a 578 KSEK (51 KEUR) sales order for a Bilberry extract product Eevia Health Plc, ("Eevia" or "The Company"), has received a 51 KEUR sales order from a European nutraceutical brand owner.
REG MAR
Eevia Health Plc enters a new stage in global sales project with an international market partner Eevia Health Plc ("Eevia" or "The Company") has collaborated with a major international ingredient house over the last 12 months on possible commercial cooperation for the global...
REG MAR
Eevia Health Plc partners up to enter 5-billion-euro eye-health market Eevia Health Plc ("Eevia" or "The Company") received a letter of Intent with a global leader in eye health for a market launch in 2025 of Retinari™, a new game-changing eye-healt...
Eevia wins new customer with starting sales order for 2,1 MSEK (188 KEUR) Eevia Health Plc ("Eevia" or "The Company") has received a first sales order for 188 KEUR (2,1 MSEK) from a large international ingredient company for Feno-Myrtillus® 25 organic...

Om Eevia Health

Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.

Webbplats
eeviahealth.com/investors
Läs mer

Handelsinformation

Kurs ()
Förändring ()
Marknad Spotlight stock market Kortnamn EEVIA ISIN-kod FI4000496658
Läs mer

IR-Kontakt

Stein Ulve IR-kontakt [email protected]